Vincenzo de Luca - Mindscape Collective

Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment

Medical Hypotheses April 5, 2023 Jianmeng Song, Yasaman Kambari, Aron Amaev et al. 2 citations

No Summary

DOI: 10.1016/j.mehy.2023.111068 Psilocybin Neuroscience Psychology Prefrontal cortex +10

118. Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?

Biological Psychiatry April 10, 2023 Aron Amaev, Jianmeng Song, Yasaman Kambari et al. 1 citation

No Summary

DOI: 10.1016/j.biopsych.2023.02.358 Psilocybin Neuroscience Psychology Radioligand +5

Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 23, 2025 Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.

Psilocybin shows promise in reducing suicidal ideation, with a systematic review revealing that 64% of participants in clinical trials experienced significant improvements in depressive symptoms. The review analyzed data from over 1,000 individuals across various studies, highlighting the potential of psychedelics in psychiatry and intensive care medicine. While adverse effects were reported in 15% of cases, they were generally mild. This evidence supports psilocybin as a valuable intervention in complementary and alternative medicine for those struggling with severe depression.

DOI: 10.1016/j.pnpbp.2025.111541 Psilocybin Adverse effect Psycinfo Medline +9

Papers

Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment

118. Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?

Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development